Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2026-03-06 @ 6:53 AM
Study NCT ID:
NCT00562068
Status:
UNKNOWN
Last Update Posted:
2013-08-26
First Post:
2007-11-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
Sponsor:
Cancer Research UK
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
CDR0000576439
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None